Commercial Physical & Biological Research Industry - SEC Form 4 Insider Trading Screener

Services Sector - Engineering, Accounting, Research, Management Services - Commercial Physical & Biological Research
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
100 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m
P20+5+5-3+0
S78+0+1+4+0

X

Filing Date

Trade Date

Ticker

Company

Insider Name

Insider Title

Trade Type 

Share Price

Shares Traded

Shares Owned

Own chg

Value Traded

1d ret

1w ret

1m ret

6m ret

D
2017-03-22
EXELExelixis, Inc.Hessekiel JeffreyEVP, GCS - Sale+OE$20.54-23,787274,830-8%-$488,585
M
2017-03-22
SNMXSenomyx IncPoyhonen JohnPres, CEOP - Purchase$0.98+50,000158,293+46%+$49,027+1
2017-03-20
CASCCascadian Therapeutics, Inc.Myers Scott DunsethPres, CEOP - Purchase$3.93+1,00039,416+3%+$3,927+7
D
2017-03-20
EXELExelixis, Inc.Feldbaum Carl BDirS - Sale+OE$21.77-10,00048,721-17%-$217,7000
D
2017-03-20
EXELExelixis, Inc.Papadopoulos SteliosDirS - Sale+OE$21.66-10,0001,238,471-1%-$216,6000
D
2017-03-17
INCYIncyte CorpBrooke Paul ADirS - Sale+OE$147.75-20,000196,756-9%-$2,955,000-5-6
DM
2017-03-16
INCYIncyte CorpFriedman Paul ADirS - Sale+OE$148.72-50,000297,518-14%-$7,436,164-5-6
D
2017-03-15
EXELExelixis, Inc.Willsey LanceDirS - Sale+OE$22.86-10,000568,273-2%-$228,6000-8
D
2017-03-15
EXELExelixis, Inc.Schwab GiselaPres Prod Dev, Med Aff, CMOS - Sale+OE$22.53-50,007172,027-23%-$1,126,6580-8
2017-03-06
BHRTU.S. Stem Cell, Inc.Murphy William P JrDirP - Purchase$0.02+1,200,0001,564,039+330%+$24,000
D
2017-03-16
CRLCharles River Laboratories International IncMolho DavideCorporate EVPS - Sale+OE$90.00-11,71763,566-16%-$1,054,530+1-2
2017-03-13
EXELExelixis, Inc.Cohen CharlesDirS - Sale$21.82-10,000238,180-4%-$218,200+5+1
2017-03-13
EXASExact Sciences CorpLidgard Graham PeterChief Science OfficerS - Sale$21.16-2,945343,170-1%-$62,3160+1
2017-03-13
EXASExact Sciences CorpCoward D ScottSVP, GCS - Sale$21.16-1,98354,153-4%-$41,9600+1
2017-03-13
EXASExact Sciences CorpConroy Kevin TPres, CEOS - Sale$21.16-12,059907,418-1%-$255,1680+1
2017-03-13
EXASExact Sciences CorpArora ManeeshCOOS - Sale$21.16-5,574634,537-1%-$117,9460+1
2017-03-10
CRLCharles River Laboratories International IncMolho DavideCorporate EVPS - Sale$89.71-3,19169,781-4%-$286,2540+1
2017-03-10
CRLCharles River Laboratories International IncJohst David PCorporate EVPS - Sale$89.44-7,307181,255-4%-$653,5400+1
D
2017-03-10
CRLCharles River Laboratories International IncJohst David PCorporate EVPS - Sale+OE$89.06-34,593188,562-16%-$3,080,9320+1
D
2017-03-10
EXELExelixis, Inc.Marchesi Vincent TDirS - Sale+OE$21.98-40,000120,070-25%-$879,200+1+1
D
2017-03-03
EXELExelixis, Inc.Hessekiel JeffreyEVP, GCS - Sale+OE$23.04-100,000246,617-29%-$2,303,678-2-2
DM
2017-03-03
EXELExelixis, Inc.Morrissey MichaelPres, CEOS - Sale+OE$22.72-200,000249,523-44%-$4,544,000-2-2
2017-03-03
EXELExelixis, Inc.Haley Patrick J.SVP, CommercialS - Sale$23.04-2,500140,400-2%-$57,600-2-2
2017-03-06
CRLCharles River Laboratories International IncBarbo William DCorporate EVP, CCOS - Sale$87.90-1,90020,924-8%-$167,014+1+1
D
2017-03-06
CRLCharles River Laboratories International IncBarbo William DCorporate EVP, CCOS - Sale+OE$87.78-12,54822,824-35%-$1,101,409+1+2
2017-03-03
CRLCharles River Laboratories International IncSmith David RossCorporate EVP, CFO, CAOS - Sale$88.12-3,89013,495-22%-$342,805+1+2
D
2017-03-03
CRLCharles River Laboratories International IncSmith David RossCorporate EVP, CFO, CAOS - Sale+OE$87.94-7,75017,385-31%-$681,531+1+2
D
2017-03-03
PRXLParexel International CorpPretorius SybrandSVP, Chief Scientific OfficerS - Sale+OE$65.12-8,0501,900-81%-$524,216-10
D
2017-03-03
INCRInc Research Holdings, Inc.Macdonald AlistairCEOS - Sale+OE$45.00-8,82874,468-11%-$397,260-10
2017-03-03
EXELExelixis, Inc.Senner Christopher J.EVP, CFOS - Sale$22.80-11,000102,181-10%-$250,800-2-5
D
2017-03-01
EXELExelixis, Inc.Lamb PeterEVP, Scientific Strategy, CSOS - Sale+OE$22.19-45,00089,728-33%-$998,550-2-5
DM
2017-03-01
EXELExelixis, Inc.Poste GeorgeDirS - Sale+OE$22.53-76,25077,555-50%-$1,718,185-2-5
2017-03-01
CRLCharles River Laboratories International IncBertolini Robert JDirS - Sale$88.00-6,73520,150-25%-$592,7020+2
D
2017-03-01
CRLCharles River Laboratories International IncBertolini Robert JDirS - Sale+OE$87.53-5,25526,885-16%-$459,9880+2
2017-02-27
INCYIncyte CorpHuber Reid MEVP, Chief Scientific OfficerS - Sale$131.88-2,00852,262-4%-$264,81500
2017-02-28
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale$88.48-1,270376,0180%-$112,375+1+1
2017-02-28
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale$88.03-3,772383,000-1%-$332,064+1+1
2017-02-28
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale$87.61-5,081386,772-1%-$445,167+1+1
2017-02-28
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale$87.31-5,038391,853-1%-$439,887+1+1
D
2017-02-28
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale+OE$87.09-4,910396,891-1%-$427,615+1+1
DM
2017-02-24
EXASExact Sciences CorpLidgard Graham PeterChief Science OfficerS - Sale+OE$21.51-8,668337,690-3%-$186,429+3+2
D
2017-02-27
EXASExact Sciences CorpCoward D ScottSVP, GCS - Sale+OE$21.48-7,04650,111-12%-$151,348+3+2
DM
2017-02-24
EXASExact Sciences CorpConroy Kevin TPres, CEOS - Sale+OE$21.51-27,134895,077-3%-$583,520+3+2
DM
2017-02-24
EXASExact Sciences CorpArora ManeeshCOOS - Sale+OE$21.50-11,114628,836-2%-$238,968+3+2
D
2017-02-23
INCYIncyte CorpFriedman Paul ADirS - Sale+OE$120.32-50,000297,518-14%-$6,016,000-1+2
2017-02-22
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale$88.22-3,404376,855-1%-$300,300000
2017-02-22
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale$87.84-8,658369,919-2%-$760,562000
D
2017-02-22
CRLCharles River Laboratories International IncFoster James CCOB, Pres, CEOS - Sale+OE$87.64-9,717378,577-3%-$851,592000
DM
2017-02-21
PRAHPra Health Sciences, Inc.Shannon ColinPres, CEOS - Sale+OE$61.50-100,0000-100%-$6,150,000-1-3-2
2017-02-22
SRNESorrento Therapeutics, Inc.Ji HenryPres, CEOP - Purchase$5.60+2,0002,160,8690%+$11,200-1-1-21
D
2017-02-17
NRCIANational Research CorpHays Michael D.CEO, 10%S - Sale+OE$17.45-500,0007,362,341-6%-$8,725,000+2+9+11
D
2017-02-14
PRXLParexel International CorpBatt Douglas ASVP, GC, Sec.S - Sale+OE$65.39-5,50061,479-8%-$359,645-1-2-6
D
2017-02-14
CRLCharles River Laboratories International IncMilne George M JrDirS - Sale+OE$86.52-10,71029,530-27%-$926,6290-10
A
2017-02-10
SRNESorrento Therapeutics, Inc.Ji HenryPres, CEOP - Purchase$5.15+20,00037,776+113%+$103,000+2+2-21
D
2017-02-09
PRXLParexel International CorpSaarony GadiSVP, CRSS - Sale+OE$64.54-2,32511,883-16%-$150,0560+4+2
D
2017-02-01
EXELExelixis, Inc.Lamb PeterEVP, Scientific Strategy, CSOS - Sale+OE$18.65-70,00089,680-44%-$1,305,500-1+12+13
2017-02-03
SRNESorrento Therapeutics, Inc.Wu Yue AlexanderDirP - Purchase$5.15+5,0005,000New+$25,750+8+8-6
2017-02-03
SRNESorrento Therapeutics, Inc.Janda KimDirP - Purchase$5.15+3,0003,000New+$15,450+8+8-6
2017-02-03
SRNESorrento Therapeutics, Inc.Su JeffreyEVP, COOP - Purchase$5.15+4,00013,000+44%+$20,600+8+8-6
2017-02-03
SRNESorrento Therapeutics, Inc.Herde KevinEVP, CFOP - Purchase$5.15+3,0007,000+75%+$15,450+8+8-6
2017-02-03
SRNESorrento Therapeutics, Inc.Ji HenryPres, CEOP - Purchase$5.15+20,0002,158,869+1%+$103,000+8+8-6
2017-02-03
SRNESorrento Therapeutics, Inc.Ng George KSee RemarksS - Sale$5.15-40,00064,239-38%-$206,000+8+8-6
2017-02-03
SRNESorrento Therapeutics, Inc.Shah JaisimDirP - Purchase$5.15+10,000102,631+11%+$51,500+8+8-6
2017-02-03
SRNESorrento Therapeutics, Inc.Zeldis Jerome BSee RemarksP - Purchase$5.15+10,00010,000New+$51,500+8+8-6
2017-02-02
CASCCascadian Therapeutics, Inc.Love Ted WDirP - Purchase$4.24+23,00027,209+546%+$97,520+4+1-3
2017-01-30
CASCCascadian Therapeutics, Inc.Henney Christopher SDirP - Purchase$4.11+25,32450,000+103%+$103,973+300
D
2017-01-30
CRLCharles River Laboratories International IncJohst David PCorporate EVPS - Sale+OE$78.00-13,950160,746-8%-$1,088,100+1+2+8
2017-01-27
CASCCascadian Therapeutics, Inc.Myers Scott DunsethPres, CEOP - Purchase$3.76+20,50038,416+114%+$77,039+2+7+3
M
2017-01-27
LUNALuna Innovations IncCarilion Health System10%S - Sale$1.99-84,5662,164,330-4%-$167,944-1+4-6
2017-01-20
INCRInc Research Holdings, Inc.Gaenzle Christopher LCAO, GC, SecS - Sale$50.09-1,18639,037-3%-$59,4060+4+8
DM
2017-01-20
INCRInc Research Holdings, Inc.Rush Gregory SEVP, CFOS - Sale+OE$50.57-2,90744,209-6%-$147,0040+4+8
2017-01-20
INCRInc Research Holdings, Inc.Macdonald AlistairCEOS - Sale$50.50-1,37552,854-3%-$69,4380+4+8
DM
2017-01-13
NRCIANational Research CorpHays Michael D.CEO, 10%S - Sale+OE$18.48-14,2967,862,3410%-$264,202-10-3
D
2017-01-11
NRCIANational Research CorpHays Michael D.CEO, 10%S - Sale+OE$19.00-7007,876,6370%-$13,3000-2-1
2017-01-09
INCYIncyte CorpHuber Reid MEVP, Chief Scientific OfficerS - Sale$113.55-11,73952,185-18%-$1,332,963+20+6
DM
2017-01-06
NRCIANational Research CorpHays Michael D.CEO, 10%S - Sale+OE$19.24-5,4827,877,3370%-$105,467-2-5-7
D
2017-01-05
INCRInc Research Holdings, Inc.Macdonald AlistairCEOS - Sale+OE$52.19-14,84054,229-21%-$774,440+1-2+1
D
2017-01-03
EXELExelixis, Inc.Lamb PeterEVP, Scientific Strategy, CSOS - Sale+OE$14.65-70,00089,624-44%-$1,025,636+2+21+34
D
2017-01-03
EXASExact Sciences CorpCoward D ScottSVP, GCS - Sale+OE$13.61-1,53534,918-4%-$20,891+2+25+28
D
2017-01-03
INCRInc Research Holdings, Inc.Gaenzle Christopher LCAO, GC, SecS - Sale+OE$51.90-15,38341,300-27%-$798,4200+1+2
D
2017-01-03
INCRInc Research Holdings, Inc.Rush Gregory SEVP, CFOS - Sale+OE$51.90-41,42047,209-47%-$2,149,8180+1+2
D
2016-12-16
EXELExelixis, Inc.Feldbaum Carl BDirS - Sale+OE$17.03-25,00048,721-34%-$425,750-3-11+7
2016-12-14
EXASExact Sciences CorpThompson DavidDirP - Purchase$13.84+10,000136,379+8%+$138,400+4+2+39
2016-12-13
XONIntrexon CorpKirk Randal JCEO, 10%P - Purchase$28.90+34,60662,132,6530%+$1,000,113-2-5-14
2016-12-12
XONIntrexon CorpLiffman Joel DSVP, FinanceP - Purchase$28.62+8,500158,500+6%+$243,265+1+1-11
D
2016-12-09
EXELExelixis, Inc.Garber Alan MDirS - Sale+OE$16.90-7,83261,329-11%-$132,361-2-1+12
DM
2016-12-05
EXELExelixis, Inc.Scangos George ADirS - Sale+OE$17.81-204,8941,487,243-12%-$3,649,178+2-2-7
2016-12-02
AMRIAlbany Molecular Research IncMaddaluna Anthony JDirP - Purchase$16.46+1,5187,408+26%+$24,986+3+8+16
D
2016-12-02
CRLCharles River Laboratories International IncChubb Stephen DDirS - Sale+OE$71.57-4,56426,285-15%-$326,6450+3+10
2016-12-01
XONIntrexon CorpHassan FredDirP - Purchase$29.02+6,9006,900New+$200,266+6+5-8
D
2016-12-01
EXELExelixis, Inc.Lamb PeterEVP, Scientific Strategy, CSOS - Sale+OE$16.66-70,00089,624-44%-$1,166,200+3-3-16
D
2016-12-01
EXELExelixis, Inc.Schwab GiselaPres Prod Dev, Med Aff, CMOS - Sale+OE$16.73-22,000171,859-11%-$368,060+3-3-16
DM
2016-11-29
NRCIANational Research CorpHays Michael D.CEO, 10%S - Sale+OE$16.00-87,0108,391,565-1%-$1,392,160+1+10+18
D
2016-11-30
AMRIAlbany Molecular Research IncHagen Steven RSVP Manufacturing, PharmaceutS - Sale+OE$16.71-9,00034,913-20%-$150,390-1+6+14
M
2016-11-22
TENXTenax Therapeutics, Inc.Proehl Gerald TDirP - Purchase$1.67+29,88229,882New+$49,969+6+11+9
D
2016-11-28
CRLCharles River Laboratories International IncReese C RichardDirS - Sale+OE$71.93-4,53940,404-10%-$326,4850+1+6
DM
2016-11-23
NRCIANational Research CorpHays Michael D.CEO, 10%S - Sale+OE$16.00-13,0858,478,5750%-$209,3600+2+14
DM
2016-11-18
NRCIANational Research CorpHays Michael D.CEO, 10%S - Sale+OE$16.02-28,0098,491,6600%-$448,6290-1+13
D
2016-11-21
QQuintiles Ims Holdings, Inc.Greenberg Jack MDirS - Sale+OE$79.77-2,00027,930-7%-$159,5400+1-6
2016-11-16
PRAHPra Health Sciences, Inc.Kkr Fund Holdings L.P.10%S - Sale$55.51-7,500,00022,695,984-25%-$416,325,000+1+2+2

AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top